NCT05800106 - A Bioequivalence Study of Sunitinib Malate Capsules. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 4, 2018

Primary Completion Date

January 6, 2019

Study Completion Date

January 12, 2019

Conditions

Gastrointestinal Stromal TumorsRenal Cell CarcinomaPancreatic Neuroendocrine Tumor

Interventions

DRUG

Sunitinib malate capsules generic product

Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).

DRUG

Sunitinib malate capsules reference product

Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).

Trial Locations (1)

Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun